Group One Trading’s BioMarin Pharmaceuticals BMRN Stock Holding History

Group One Trading’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.01M	Buy	70,900 +6,400	+10%	+$373K	0.01%	1474
2025 Q4	$3.83M	Buy	64,500 +12,200	+23%	+$664K	0.01%	1729
2025 Q3	$2.83M	Sell	52,300 -16,900	-24%	-$967K	0.01%	1973
2025 Q2	$3.8M	Buy	69,200 +8,500	+14%	+$501K	0.01%	1548
2025 Q1	$4.29M	Buy	60,700 +33,900	+126%	+$2.28M	0.01%	1194
2024 Q4	$1.76M	Sell	26,800 -23,000	-46%	-$1.54M	﹤0.01%	2039
2024 Q3	$3.5M	Buy	49,800 +200	+0.4%	+$16.7K	0.01%	1282
2024 Q2	$4.08M	Sell	49,600 -58,400	-54%	-$4.86M	0.02%	936
2024 Q1	$9.43M	Sell	108,000 -51,300	-32%	-$4.59M	0.04%	471
2023 Q4	$15.4M	Buy	159,300 +108,400	+213%	+$9.59M	0.04%	459
2023 Q3	$4.5M	Buy	50,900 +13,600	+36%	+$1.21M	0.02%	1003
2023 Q2	$3.23M	Sell	37,300 -32,900	-47%	-$3.1M	0.01%	1310
2023 Q1	$6.83M	Buy	70,200 +27,300	+64%	+$2.83M	0.02%	670
2022 Q4	$4.44M	Buy	42,900 +20,300	+90%	+$1.91M	0.01%	1218
2022 Q3	$1.92M	Sell	22,600 -11,300	-33%	-$1.01M	﹤0.01%	1956
2022 Q2	$2.81M	Sell	33,900 -51,900	-60%	-$4.13M	﹤0.01%	1743
2022 Q1	$6.62M	Sell	85,800 -26,200	-23%	-$2.19M	0.01%	1315
2021 Q4	$9.89M	Sell	112,000 -78,000	-41%	-$6.44M	0.01%	1115
2021 Q3	$14.7M	Sell	190,000 -10,000	-5%	-$789K	0.02%	798
2021 Q2	$16.7M	Buy	200,000 +49,900	+33%	+$3.96M	0.02%	736
2021 Q1	$11.3M	Buy	150,100 +46,300	+45%	+$3.78M	0.02%	850
2020 Q4	$9.1M	Sell	103,800 -131,900	-56%	-$10.5M	0.02%	864
2020 Q3	$17.9M	Buy	235,700 +55,900	+31%	+$5.66M	0.06%	310
2020 Q2	$22.2M	Buy	179,800 +114,300	+175%	+$11.4M	0.1%	198
2020 Q1	$5.54M	Sell	65,500 -15,100	-19%	-$1.3M	0.04%	486
2019 Q4	$6.82M	Buy	80,600 +33,300	+70%	+$2.52M	0.05%	515
2019 Q3	$3.19M	Sell	47,300 -4,700	-9%	-$362K	0.03%	872
2019 Q2	$4.45M	Sell	52,000 -400	-0.8%	-$34.2K	0.04%	590
2019 Q1	$4.66M	Buy	52,400 +5,700	+12%	+$528K	0.05%	465
2018 Q4	$3.98M	Buy	46,700 +4,100	+10%	+$390K	0.03%	624
2018 Q3	$4.13M	Sell	42,600 -33,000	-44%	-$3.29M	0.03%	684
2018 Q2	$7.12M	Buy	75,600 +39,700	+111%	+$3.48M	0.06%	376
2018 Q1	$2.91M	Sell	35,900 -56,600	-61%	-$4.86M	0.03%	753
2017 Q4	$8.25M	Buy	92,500 +44,000	+91%	+$3.83M	0.06%	410
2017 Q3	$4.51M	Sell	48,500 -1,400	-3%	-$124K	0.04%	559
2017 Q2	$4.53M	Buy	49,900 +3,300	+7%	+$300K	0.05%	494
2017 Q1	$4.09M	Sell	46,600 -14,600	-24%	-$1.3M	0.05%	489
2016 Q4	$5.07M	Sell	61,200 -64,500	-51%	-$5.55M	0.05%	444
2016 Q3	$11.6M	Buy	125,700 +39,200	+45%	+$3.69M	0.13%	158
2016 Q2	$6.73M	Buy	86,500 +21,400	+33%	+$1.82M	0.08%	285
2016 Q1	$5.37M	Sell	65,100 -16,600	-20%	-$1.35M	0.08%	318
2015 Q4	$8.56M	Sell	81,700 -8,600	-10%	-$898K	0.1%	201
2015 Q3	$9.51M	Sell	90,300 -25,600	-22%	-$3.42M	0.13%	160
2015 Q2	$15.9M	Sell	115,900 -28,000	-19%	-$3.47M	0.22%	75
2015 Q1	$17.9M	Sell	143,900 -41,400	-22%	-$4.39M	0.28%	47
2014 Q4	$16.8M	Buy	185,300 +26,400	+17%	+$2.2M	0.25%	62
2014 Q3	$11.5M	Buy	158,900 +46,900	+42%	+$3.08M	0.18%	95
2014 Q2	$6.97M	Buy	112,000 +25,500	+29%	+$1.54M	0.11%	195
2014 Q1	$5.9M	Buy	86,500 +5,400	+7%	+$398K	0.1%	184
2013 Q4	$5.7M	Buy	81,100 +81,000	+81,000%	+$5.5M	0.09%	225
2013 Q3	$7K	Sell	100 -5,500	-98%	-$366K	﹤0.01%	4615
2013 Q2	$312K	Buy	+5,600	New	+$349K	0.01%	1758

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Group One Trading's BMRN Position: Q1 2026 in Review

Group One Trading sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 7,641 shares — an estimated $446K sold.

Group One Trading first reported a position in BMRN in Q3 2013 and held it in 43 quarters. The position peaked at $12.5M in Q4 2020. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Group One Trading reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Group One Trading sold 7,641 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $446K.
Group One Trading first reported a position in BioMarin Pharmaceuticals in Q3 2013 and held it in 43 quarters.
Group One Trading's BioMarin Pharmaceuticals position peaked at $12.5M in Q4 2020.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.